The Y14-p53 regulatory circuit in megakaryocyte differentiation and thrombocytopenia

Area of Science:

• Hematology
• Genetics
• Molecular Biology

Background:

• Thrombocytopenia-absent radius (TAR) syndrome is a rare genetic disorder.
• It is characterized by upper limb malformations and severe thrombocytopenia.
• The genetic basis of TAR syndrome is linked to mutations in the RBM8A gene.

Purpose of the Study:

• To investigate the role of RBM8A in megakaryocyte development and platelet production.
• To elucidate the underlying molecular mechanisms of thrombocytopenia in TAR syndrome.
• To explore potential therapeutic strategies targeting the identified pathways.

Main Methods:

• Generation of megakaryocyte-specific Rbm8a knockout (Rbm8aKO^MK) mice.
• Analysis of megakaryocyte ploidy, differentiation, and platelet parameters in knockout mice.
• Depletion of Y14 (RBM8A) in human erythroleukemia (HEL) cells.
• Assessment of p53 and p21 expression and cell-cycle regulation.
• Pharmacological inhibition and genetic knockout of p53.

Main Results:

• Rbm8aKO^MK mice displayed significant thrombocytopenia, internal hemorrhage, and splenomegaly.
• Immature, low-ploidy megakaryocytes accumulated in the bone marrow of knockout mice.
• Y14 depletion in HEL cells impaired polyploidization and increased p53/p21 levels.
• p53 inhibition or knockout partially restored megakaryocyte differentiation and platelet counts in Rbm8aKO^MK mice.
• p53 inhibition also unexpectedly increased Y14 expression in HEL cells.

Conclusions:

• RBM8A insufficiency directly causes a disorder of platelet production, as evidenced by the Rbm8aKO^MK mouse model.
• The Y14-p53 signaling axis plays a critical role in megakaryocyte maturation and platelet biogenesis.
• Targeting the p53 pathway presents a potential therapeutic avenue for TAR syndrome.